查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
生物製药第三方物流市场-全球市场规模、份额、趋势分析、机会和预测报告，2019-2029
市场调查报告书
商品编码
1319294

生物製药第三方物流市场-全球市场规模、份额、趋势分析、机会和预测报告，2019-2029

Biopharmaceutical Third-party Logistics Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Supply Chain ; By Services ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2029年全球生物製药第三方物流（3PL）市场规模将达到1496.2亿美元

由于对专业处理和存储的需求不断增长以及生物製药供应链的日益复杂性，全球生物製药第三方物流 (3PL) 市场正在蓬勃发展。

领先的战略咨询和市场研究公司 BlueWeave Consulting 最近估计，2022 年全球生物製药第三方物流 (3PL) 市场价值将达到 1005 亿美元。 BlueWeave预测，2023年至2029年的预测期内，全球生物製药第三方物流（3PL）市场规模将以5.9%的复合年复合成长率显着增长，到2029年达到1496.2亿美元。我来了。全球生物製药第三方物流 (3PL) 市场的主要增长促进因素包括物流外包的日益普及、由于销售量可观而加强製药行业分销网络的努力以及生物仿製药产品的增加。生物製药行业在开发救生药物以对抗癌症、糖尿病、呼吸系统疾病和心血管疾病等慢性疾病方面取得了重大进展。因此，随着生物製药意识的增强，消费者的需求也在增加。此外，在运输过程中采用带有温度控制系统的先进车辆，再加上尽量减少潜在损坏和人为错误的努力，已成为推动生物製药 3PL 市场增长的关键因素。这些进步使生物药品运输变得更安全、更可靠。然而，严格的质量控制和风险管理预计将在分析期间抑制整体市场的增长。

该报告的详细分析提供了有关全球生物製药第三方物流（3PL）市场的增长潜力、未来趋势和统计数据的信息。它还涵盖了推动市场总规模预测的因素。该报告致力于为决策者提供全球生物製药第三方物流（3PL）市场的最新技术趋势以及行业见解，以做出明智的战略决策。它还分析了市场的增长促进因素、挑战和竞争力。

目录

第1章研究框架

第2章执行摘要

第3章全球生物製药第三方物流市场洞察

  • 行业价值链分析
  • DROC分析
    • 增长促进因素
      • 复杂的生物製药供应链
      • 对专业处理和存储的需求不断增长
    • 抑制因素
      • 严格的质量控制和风险管理
    • 机会
      • 科技的发展
    • 任务
      • 复杂的供应链要求
  • 技术进步/最新发展
  • 监管框架
  • 波特五力分析

第4章全球生物医药第三方物流市场概况

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 按供应链
      • 新鲜食品的）低温运输系统
      • 非冷链
    • 按服务
      • 交通设施
      • 空运货物
      • 海运
      • 陆路
      • 仓库和储存
      • 其他的
    • 按地区
      • 北美
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲 (MEA)

第5章北美生物医药第三方物流市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 按供应链
    • 按服务
    • 按国家/地区
      • 我们
      • 加拿大

第6章欧洲生物製药第三方物流市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 按供应链
    • 按服务
    • 按国家/地区
      • 德国
      • 英国
      • 意大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他欧洲国家

第7章亚太生物医药第三方物流市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 按供应链
    • 按服务
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳大利亚和新西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 亚太地区其他地区

第8章拉美生物医药第三方物流市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 按供应链
    • 按服务
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 拉丁美洲其他地区

第9章中东及非洲生物医药第三方物流市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 按供应链
    • 按服务
    • 按国家/地区
      • 沙特阿拉伯
      • 阿拉伯联合酋长国
      • 卡塔尔
      • 科威特
      • 南非
      • 尼日利亚
      • 阿尔及利亚
      • MEA 的其余部分

第10章竞争格局

  • 主要公司及其产品列表
  • 2022年全球生物医药第三方物流企业市场份额分析
  • 通过运行参数进行竞争基准测试
  • 主要战略发展（合併、收购、合作伙伴关係等）

第11章COVID-19对全球生物製药第三方物流市场的影响

第12章公司简介（公司简介、财务矩阵、竞争格局、关键人才、主要竞争、联繫地址、战略展望、SWOT分析）

  • DHL International GmbH
  • SF Express
  • United Parcel Service of America, Inc.
  • AmerisourceBergen Corp.
  • DB Schenker
  • Kuehne and Nagel
  • Kerry Logistics Network Ltd.
  • Agility
  • McKesson Corporation
  • FedEx
  • Other Prominent Players

第13章关键战略建议

第14章调查方法

  • 定性研究
    • 初级和次级研究
  • 定量研究
  • 市场细分和数据三角测量
    • 二次调查
    • 初步调查
  • 主要调查受访者的地区分布
  • 假设和限制
简介目录
Product Code: BWC23598

Global Biopharmaceutical Third-party Logistics (3PL) Market Size Set to Touch USD 149.62 Billion by 2029.

Global biopharmaceutical Third-party Logistics (3PL) market is flourishing because of an increasing need for specialized handling and storage and growing complexity of the biopharmaceutical supply chain.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global biopharmaceutical third-party logistics (3PL) market size at USD 100.5 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global biopharmaceutical third-party logistics (3PL) market size to grow at a significant CAGR of 5.9% reaching a value of USD 149.62 billion by 2029. Major growth drivers for the global biopharmaceutical third-party logistics (3PL) market include an increasing prevalence of logistics outsourcing, the pharmaceutical industry's commitment to enhancing their distribution networks due to impressive sales figures, and a rise in the introduction of biosimilar products. The biopharmaceutical sector has made remarkable strides in developing life-saving drugs to combat chronic illnesses such as cancer, diabetes, respiratory diseases, and cardiovascular diseases. As a result, consumer demand has escalated in tandem with the growing awareness about biopharmaceuticals. Also, the adoption of advanced vehicles equipped with temperature control systems during transportation, coupled with efforts to minimize potential damage and human errors, has emerged as critical factors propelling the growth of the biopharmaceutical 3PL market. These advancements have elevated the safety and dependability of transporting biopharmaceutical products. However, stringent quality control and risk management is anticipated to restrain the overall market growth during the period in analysis.

Global Biopharmaceutical Third-party Logistics (3PL) Market - Overview:

The global biopharmaceutical third-party logistics (3PL) market encompasses the outsourcing of logistics and supply chain management services by biopharmaceutical companies to specialized providers. These services involve the transportation, warehousing, inventory management, and distribution of biopharmaceutical products, ensuring their safe and timely delivery to different locations worldwide. The increasing number of elderly individuals, escalating occurrence of chronic illnesses, rising healthcare spending, and the surging demand for biopharmaceutical drugs are among the primary drivers necessitating the secure and punctual transportation of medications to various locations. This exponential demand for third-party logistics (3PL) services is rapidly gaining momentum. In addition to biopharmaceuticals, the global patient population is increasingly embracing biosimilar medications, leading to a substantial surge in demand. The remarkable growth of biosimilar medicines is expected to make a substantial contribution to the expansion of the market during the forecast period.

Impact of COVID-19 on Global Biopharmaceutical Third-party Logistics (3PL) Market:

COVID-19 pandemic adversely affected global biopharmaceutical third-party logistics (3PL) market. While the pandemic led to disruptions in global supply chains, the biopharmaceutical industry faced unique challenges in terms of increased demand for essential medical supplies and vaccines. The need for temperature-controlled storage, secure transportation, and timely delivery became even more critical. Logistics providers had to adapt quickly to ensure uninterrupted supply chain operations while adhering to stringent health and safety measures. Additionally, the pandemic accelerated the adoption of digital solutions and advanced technologies to enable remote monitoring, real-time tracking, and efficient inventory management. Despite the challenges, the pandemic highlighted the importance of robust logistics networks, resulting in an increased focus on enhancing the resilience and agility of the biopharmaceutical third-party logistics (3PL) market.

Global Biopharmaceutical Third-party Logistics (3PL) Market - By Services:

Based on services, the global biopharmaceutical third-party logistics (3PL) market is split into Transportation and Warehousing & Storage segments. The warehousing & storage segment holds a higher share in the global biopharmaceutical third-party logistics (3PL) market, due to the significant surge in demand for warehousing and storage services within the life sciences and pharmaceutical sectors. These services play a crucial role in reducing overhead costs for life science companies and contribute to improving their profitability. Service providers in this segment are also offering value-added services, such as warehousing and packaging, which further attract pharmaceutical companies. Also, the incorporation of robots and code scanners has effectively reduced turnaround times, thus driving the growth of the warehousing and storage segment.

Competitive Landscape:

Major players operating in the global biopharmaceutical third-party logistics (3PL) market include: DHL International GmbH, SF Express, United Parcel Service of America, Inc., AmerisourceBergen Corp., DB Schenker, Kuehne and Nagel, Kerry Logistics Network Ltd., Agility, McKesson Corporation, and FedEx. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Biopharmaceutical Third-party Logistics (3PL) Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Biopharmaceutical Third-party Logistics (3PL) Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Biopharmaceutical Third-party Logistics Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing Complexity of the Biopharmaceutical Supply Chain
      • 3.2.1.2. Rising Need for Specialized Handling and Storage
    • 3.2.2. Restraints
      • 3.2.2.1. Stringent Quality Control and Risk Management
    • 3.2.3. Opportunities
      • 3.2.3.1. Advancement in Technology
    • 3.2.4. Challenges
      • 3.2.4.1. Complex Supply Chain Requirements
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Biopharmaceutical Third-party Logistics Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share & Forecast
    • 4.2.1. By Supply Chain
      • 4.2.1.1. Cold Chain
      • 4.2.1.2. Non-cold Chain
    • 4.2.2. By Services
      • 4.2.2.1. Transportation
      • 4.2.2.1.1. Air Freight
      • 4.2.2.1.2. Sea Freight
      • 4.2.2.1.3. Overland
      • 4.2.2.2. Warehousing & Storage
      • 4.2.2.3. Others
    • 4.2.3. By Region
      • 4.2.3.1. North America
      • 4.2.3.2. Europe
      • 4.2.3.3. Asia Pacific (APAC)
      • 4.2.3.4. Latin America (LATAM)
      • 4.2.3.5. Middle East and Africa (MEA)

5. North America Biopharmaceutical Third-party Logistics Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Supply Chain
    • 5.2.2. By Services
    • 5.2.3. By Country
      • 5.2.3.1. United States
      • 5.2.3.1.1. By Supply Chain
      • 5.2.3.1.2. By Services
      • 5.2.3.2. Canada
      • 5.2.3.2.1. By Supply Chain
      • 5.2.3.2.2. By Services

6. Europe Biopharmaceutical Third-party Logistics Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Supply Chain
    • 6.2.2. By Services
    • 6.2.3. By Country
      • 6.2.3.1. Germany
      • 6.2.3.1.1. By Supply Chain
      • 6.2.3.1.2. By Services
      • 6.2.3.2. United Kingdom
      • 6.2.3.2.1. By Supply Chain
      • 6.2.3.2.2. By Services
      • 6.2.3.3. Italy
      • 6.2.3.3.1. By Supply Chain
      • 6.2.3.3.2. By Services
      • 6.2.3.4. France
      • 6.2.3.4.1. By Supply Chain
      • 6.2.3.4.2. By Services
      • 6.2.3.5. Spain
      • 6.2.3.5.1. By Supply Chain
      • 6.2.3.5.2. By Services
      • 6.2.3.6. Belgium
      • 6.2.3.6.1. By Supply Chain
      • 6.2.3.6.2. By Services
      • 6.2.3.7. Russia
      • 6.2.3.7.1. By Supply Chain
      • 6.2.3.7.2. By Services
      • 6.2.3.7.3.
      • 6.2.3.8. The Netherlands
      • 6.2.3.8.1. By Supply Chain
      • 6.2.3.8.2. By Services
      • 6.2.3.9. Rest of Europe
      • 6.2.3.9.1. By Supply Chain
      • 6.2.3.9.2. By Services

7. Asia-Pacific Biopharmaceutical Third-party Logistics Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Supply Chain
    • 7.2.2. By Services
    • 7.2.3. By Country
      • 7.2.3.1. China
      • 7.2.3.1.1. By Supply Chain
      • 7.2.3.1.2. By Services
      • 7.2.3.2. India
      • 7.2.3.2.1. By Supply Chain
      • 7.2.3.2.2. By Services
      • 7.2.3.3. Japan
      • 7.2.3.3.1. By Supply Chain
      • 7.2.3.3.2. By Services
      • 7.2.3.4. South Korea
      • 7.2.3.4.1. By Supply Chain
      • 7.2.3.4.2. By Services
      • 7.2.3.5. Australia & New Zealand
      • 7.2.3.5.1. By Supply Chain
      • 7.2.3.5.2. By Services
      • 7.2.3.6. Indonesia
      • 7.2.3.6.1. By Supply Chain
      • 7.2.3.6.2. By Services
      • 7.2.3.7. Malaysia
      • 7.2.3.7.1. By Supply Chain
      • 7.2.3.7.2. By Services
      • 7.2.3.8. Singapore
      • 7.2.3.8.1. By Supply Chain
      • 7.2.3.8.2. By Services
      • 7.2.3.9. Vietnam
      • 7.2.3.9.1. By Supply Chain
      • 7.2.3.9.2. By Services
      • 7.2.3.10. Rest of APAC
      • 7.2.3.10.1. By Supply Chain
      • 7.2.3.10.2. By Services

8. Latin America Biopharmaceutical Third-party Logistics Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Supply Chain
    • 8.2.2. By Services
    • 8.2.3. By Country
      • 8.2.3.1. Brazil
      • 8.2.3.1.1. By Supply Chain
      • 8.2.3.1.2. By Services
      • 8.2.3.2. Mexico
      • 8.2.3.2.1. By Supply Chain
      • 8.2.3.2.2. By Services
      • 8.2.3.3. Argentina
      • 8.2.3.3.1. By Supply Chain
      • 8.2.3.3.2. By Services
      • 8.2.3.4. Peru
      • 8.2.3.4.1. By Supply Chain
      • 8.2.3.4.2. By Services
      • 8.2.3.5. Rest of LATAM
      • 8.2.3.5.1. By Supply Chain
      • 8.2.3.5.2. By Services

9. Middle East & Africa Biopharmaceutical Third-party Logistics Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Supply Chain
    • 9.2.2. By Services
    • 9.2.3. By Country
      • 9.2.3.1. Saudi Arabia
      • 9.2.3.1.1. By Supply Chain
      • 9.2.3.1.2. By Services
      • 9.2.3.2. UAE
      • 9.2.3.2.1. By Supply Chain
      • 9.2.3.2.2. By Services
      • 9.2.3.3. Qatar
      • 9.2.3.3.1. By Supply Chain
      • 9.2.3.3.2. By Services
      • 9.2.3.4. Kuwait
      • 9.2.3.4.1. By Supply Chain
      • 9.2.3.4.2. By Services
      • 9.2.3.5. South Africa
      • 9.2.3.5.1. By Supply Chain
      • 9.2.3.5.2. By Services
      • 9.2.3.6. Nigeria
      • 9.2.3.6.1. By Supply Chain
      • 9.2.3.6.2. By Services
      • 9.2.3.7. Algeria
      • 9.2.3.7.1. By Supply Chain
      • 9.2.3.7.2. By Services
      • 9.2.3.8. Rest of MEA
      • 9.2.3.8.1. By Supply Chain
      • 9.2.3.8.2. By Services

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Biopharmaceutical Third-party Logistics Company Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Biopharmaceutical Third-party Logistics Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. DHL International GmbH
  • 12.2. SF Express
  • 12.3. United Parcel Service of America, Inc.
  • 12.4. AmerisourceBergen Corp.
  • 12.5. DB Schenker
  • 12.6. Kuehne and Nagel
  • 12.7. Kerry Logistics Network Ltd.
  • 12.8. Agility
  • 12.9. McKesson Corporation
  • 12.10. FedEx
  • 12.11. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations